WuXi AppTec Co., Ltd. (603259.SS)
| Previous close | 41.60 |
| Open | 41.38 |
| Bid | 42.91 x 0 |
| Ask | 42.92 x 0 |
| Day's range | 41.30 - 43.13 |
| 52-week range | 41.17 - 93.56 |
| Volume | |
| Avg. volume | 96,190,446 |
| Market cap | 121.758B |
| Beta (5Y monthly) | 0.68 |
| PE ratio (TTM) | 13.25 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 0.89 (2.15%) |
| Ex-dividend date | 14 Jun 2023 |
| 1y target est | N/A |
- PR Newswire
WuXi AppTec Revenue Surpassed RMB40 Billion in 2023, and Adjusted Non-IFRS Net Profit Exceeded RMB10 Billion for the First Time
WuXi AppTec (stock code: 603259.SH / 2359.HK), a global company that provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical and life sciences industry, today announced its financial results for the year ending December 31, 2023 ("Reporting Period"):
- PR Newswire
WuXi Advanced Therapies Receives FDA Approval to Manufacture Iovance's AMTAGVI™ (lifileucel) for Advanced Melanoma
WuXi Advanced Therapies (WuXi ATU), a wholly owned subsidiary of WuXi AppTec, today announced that the U.S. Food and Drug Administration (FDA) has approved its Philadelphia site to begin the analytical testing and manufacturing of AMTAGVI for Iovance, which received FDA accelerated approval of its Biologics License Application (BLA) on February 16, 2024.
- PR Newswire
WuXi AppTec Triples Peptide Manufacturing Capacity and Launches the New Taixing API Manufacturing Site
WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries to advance discoveries and deliver groundbreaking treatments to patients, announced the commissioning of its two new peptide manufacturing plants, one at its Changzhou facility and another at the new Taixing site in China. This significant expansion has increased the company's Solid-Phase Peptide Synthesis (SPPS) total
